Doximity
DOCS NYSE· Health Care Technology
Last close · Oct 23, 2026
$33.39
KIRA · Stoqly’s AI analyst, in plain words
- Doximity had $645M of revenue in fiscal 2026, up 13.1% on the year before. Over five years, revenue changed +25.5% a year on average.
- Its operating margin was 33.3%, down 6.6 pts: of every 100 in sales, about 33 is left after running the business.
- Doximity made $196M of net profit in fiscal 2026. From fiscal 2020 to 2026, diluted EPS grew 40.0% a year.
- Free cash flow was $326M in fiscal 2026, 50.6% of revenue.
- Doximity returned $432M to shareholders in fiscal 2026, 132% of free cash flow. The diluted share count fell 1.1%.
- Doximity has $749M more cash than debt.
Market cap
$6.4B
P/E
39.3x
Revenue
$645M
Net income
$196M
Free cash flow
$326M
Operating margin
33.3%
Doximity in 30 seconds · fiscal 2026
Are sales growing?
+13.1%
Yes. Sales grew 13.1% last year.
Does it make a profit?
30.4%
Yes. It keeps 30.4% of every sale as profit.
Does profit turn into cash?
50.6%
Yes. 50.6% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
39.3x
One share costs 39.3 times its yearly profit per share. Typical for its sector: 27.9x.
What Doximity does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · May 19, 2026
- Legal name
- Doximity, Inc.
- CIK
- 0001516513
Doximity · DOCS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $344M | $419M | $475M | $570M | $645M |
| Revenue growth | 66.1% | 22.0% | 13.5% | 20.0% | 13.1% |
| Gross margin | 88.4% | 87.2% | 89.3% | 90.2% | 89.1% |
| Operating margin | 33.1% | 29.9% | 34.5% | 39.9% | 33.3% |
| Net income | $155M | $113M | $148M | $223M | $196M |
| Net margin | 45.1% | 26.9% | 31.0% | 39.1% | 30.4% |
| Diluted EPS | $0.70 | $0.53 | $0.72 | $1.11 | $0.98 |
| Cash | |||||
| Cash from operations | $127M | $180M | $184M | $273M | $327M |
| Capital expenditure | $1.9M | $1.7M | $0.1M | $0.0M | $0.0M |
| Free cash flow | $125M | $178M | $184M | $273M | $326M |
| FCF margin | 36.3% | 42.5% | 38.7% | 47.9% | 50.6% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $2.7M | $85.3M | $281M | $120M | $432M |
| Share count change | 100.8% | 11.7% | −3.6% | −2.2% | −1.1% |
| Debt and strength | |||||
| Cash and short-term investments | $708M | $809M | $763M | $916M | $749M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $879M | $966M | $901M | $1.1B | $951M |
| Net debt / EBITDA | −6.0x | −6.0x | −4.4x | −3.8x | −3.3x |
| Current ratio | 8.1x | 7.0x | 6.2x | 7.0x | 6.1x |
| Returns and quality | |||||
| Return on capital | — | 64.8% | 88.4% | 126.3% | 91.3% |
| Return on equity | 32.8% | 12.2% | 15.8% | 22.5% | 19.3% |
| Piotroski F-score | — | 3 | 6 | 8 | 4 |
| Altman Z'' | 14.8 | 12.1 | 11.2 | 12.8 | 11.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.2M
4 insiders
Of sales under plans
100%
$2.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Doximity · DOCS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Doximity DOCS | $6.4B | 13.1% | 33.3% | 50.6% | 91.3% | 39.3x | 4 |
| Certara CERT | $1.6B | 8.8% | 5.0% | 22.6% | 0.9% | — | 5 |
| HealthStream HSTM | $1.0B | 4.3% | 6.7% | 19.6% | — | 48.8x | — |
| Veeva Systems VEEV | $52.5B | 16.3% | 28.7% | 43.4% | — | 52.1x | 6 |
| Solventum SOLV | $14.9B | 0.9% | 26.2% | −0.1% | 20.4% | 10.5x | 5 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $33.39 a share, the company is worth $6.4B: 39.3 times its earnings of the last four quarters.
Doximity grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 1 of 3.
Source: SEC EDGAR XBRL filings (CIK 0001516513). Data updated October 14, 2026. For information only — not investment advice. Check the original filings before relying on any figure.